Alterations in HLA Class I-Presented Immunopeptidome and Class I-Interactome upon Osimertinib Resistance in EGFR Mutant Lung Adenocarcinoma.

Qi, Yue A; Maity, Tapan K; Gao, Shaojian; Gong, Tao; Bahta, Meriam; Venugopalan, Abhilash; Zhang, Xu; Guha, Udayan

Qi, Yue A; Maity, Tapan K; Gao, Shaojian; Gong, Tao; Bahta, Meriam; Venugopalan, Abhilash; Zhang, Xu; Guha, Udayan.

Afiliação

Qi YA; Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Maity TK; Center for Alzheimer's and Related Dementias, National Institute on Aging, NIH, Bethesda, MD 20892, USA.
Gao S; Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Gong T; Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Bahta M; Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Venugopalan A; Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Zhang X; Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.
Guha U; Thoracic and GI Malignancies Branch, Center for Cancer Research, NCI, NIH, Bethesda, MD 20892, USA.

Cancers (Basel) ; 13(19)2021 Oct 04.

Article em En | MEDLINE | ID: mdl-34638461

Palavras-chave

HLA; SILAC; antigen presentation; immune evasion; immunopeptidome; lung adenocarcinoma; osimertinib resistance; proteomics

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google